Sitaxentan

Generic Name
Sitaxentan
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C18H15ClN2O6S2
CAS Number
184036-34-8
Unique Ingredient Identifier
J9QH779MEM
Background

Sitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan from the market over concerns of hepatotoxicity.

Indication

Investigated for use/treatment in pulmonary hypertension, connective tissue diseases, hypertension, and congestive heart failure.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Drug Interaction Between Ritonavir And Sitaxsentan

First Posted Date
2010-12-02
Last Posted Date
2015-03-05
Lead Sponsor
Pfizer
Registration Number
NCT01251848

Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan

First Posted Date
2010-12-02
Last Posted Date
2015-03-05
Lead Sponsor
Pfizer
Registration Number
NCT01251835

A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses

First Posted Date
2010-11-19
Last Posted Date
2012-02-22
Lead Sponsor
Pfizer
Target Recruit Count
16
Registration Number
NCT01244620
Locations
🇸🇬

Pfizer Investigational Site, Singapore, Singapore

Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients

Phase 3
Terminated
Conditions
Hypertension, Pulmonary
Interventions
Drug: Sitaxentan
First Posted Date
2010-09-28
Last Posted Date
2011-12-14
Lead Sponsor
Pfizer
Target Recruit Count
2
Registration Number
NCT01210443
Locations
🇯🇵

Pfizer Investigational Site, Shinjyuku-ku, Tokyo, Japan

A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients

Phase 3
Terminated
Conditions
Hypertension, Pulmonary
Interventions
Drug: Sitaxentan
First Posted Date
2010-09-17
Last Posted Date
2011-12-01
Lead Sponsor
Pfizer
Target Recruit Count
2
Registration Number
NCT01204853
Locations
🇯🇵

Pfizer Investigational Site, Shinjyuku-ku, Tokyo, Japan

Role of Endothelin-A (ETA) and Endothelin-B (ETB) Receptors in the Vasodilatory Response to Endothelin-3 (ET-3)

First Posted Date
2010-04-09
Last Posted Date
2015-07-21
Lead Sponsor
University of Edinburgh
Target Recruit Count
10
Registration Number
NCT01100736
Locations
🇬🇧

Clinical Research Centre, Western General Hospital, Edinburgh, Scotland, United Kingdom

Study on the Effects of Sitaxsentan on Airway Remodeling in Patients With Severe Asthma

First Posted Date
2010-01-15
Last Posted Date
2012-05-10
Lead Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Target Recruit Count
17
Registration Number
NCT01050491
Locations
🇫🇷

Clinical Investigation center 07, Hopital Bichat, Paris, France

Sitaxsentan in Proteinuric Chronic Kidney Disease

First Posted Date
2009-01-06
Last Posted Date
2009-01-06
Lead Sponsor
University of Edinburgh
Target Recruit Count
27
Registration Number
NCT00817037
Locations
🇬🇧

Clinical Research Centre, Western General Hospital, Edinburgh, Scotland, United Kingdom

A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension

Phase 3
Terminated
Conditions
Pulmonary Arterial Hypertension
Interventions
Drug: Sitaxsentan
First Posted Date
2008-12-18
Last Posted Date
2012-04-24
Lead Sponsor
Pfizer
Target Recruit Count
1192
Registration Number
NCT00811018
Locations
🇬🇧

Pfizer Investigational Site, Newcastle, United Kingdom

Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety

First Posted Date
2008-11-24
Last Posted Date
2018-10-25
Lead Sponsor
Pfizer
Target Recruit Count
3
Registration Number
NCT00796510
Locations
🇺🇦

Pfizer Investigational Site, Kyiv, Ukraine

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy